For applications filed on or after January 1, 2027, Medicaid pays for fewer past bills, raising Alzheimer's testing costs for late applicants. Retroactive coverage, the benefit that pays eligible pre-application bills, shrinks from three months to one month for expansion adults and two months for others. The Pennsylvania Health Law Project describes this change in its October coverage explainer.
Alzheimer's symptoms often lead to urgent visits before families finish Medicaid paperwork. Testing can span several appointments, scans and lab work. Bills from that period may now fall outside the shorter payback window.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Usc — Use this primary source to verify the official guidance.
- Read the official guidance from CMS — Use this primary source to verify the official guidance.
Table of Contents
- Who keeps one month and who keeps two?
- Why does late diagnosis raise the stakes?
- Which Alzheimer's tests face coverage gaps?
- What should families do before applying?
Who keeps one month and who keeps two?
The one-month group is expansion adults ages 19 to 64 with income up to 138% of poverty. Older adults 65 and older, people with disabilities, children and other groups keep up to two months. The distinction matters because age and disability status place most new Alzheimer's patients in the two-month group.
H.R. 1, signed July 4, 2025, sets the change for applications filed on or after January 1, 2027. Retroactive coverage now pays qualifying hospital, emergency, nursing-home and rehabilitation bills from before applying. That protection helps patients who seek care first and complete paperwork later.
Why does late diagnosis raise the stakes?
Alzheimer's is diagnosed on average 3.5 years after symptoms appear. Families often pay for evaluations, referrals and repeat visits during that delay. A shorter retroactive window covers less of that look-back period.
Earlier treatment lowers later spending, according to USC Schaeffer Center modeling in its early-treatment analysis. The model finds about $1,640 lower annual Medicaid costs per patient, or 13%, plus caregiving savings. Delayed confirmation can therefore affect both health and household budgets.
Which Alzheimer's tests face coverage gaps?
A new workup often pairs cognitive evaluation with amyloid confirmation by PET, spinal-fluid test or blood biomarker. Disease-modifying drugs lecanemab and donanemab require biomarker confirmation before use. Families may need one of these tests before a doctor can prescribe. Access is uneven.
In May 2025 the FDA cleared Fujirebio Lumipulse G pTau217/β-Amyloid 1-42 for symptomatic adults, yet a physician review found only 18 of 51 state Medicaid programs mention Alzheimer's blood tests in public documents, as reported by KevinMD in its state coverage review. For PET, CMS reported on Oct. 13, 2023 that it removed the national coverage determination in its CMS roundup. That action ended the one-scan limit and left decisions to regional contractors.
What should families do before applying?
People with memory symptoms should apply for Medicaid immediately and save every bill. The Center on Budget and Policy Priorities notes that pre-application diagnostic costs outside the shorter window will fall on patients or providers.
Waiting to gather records can cost coverage. Take these steps while symptoms are evaluated: Bring those records to the caseworker and the billing office. Clear dates show which services fall inside the one-month or two-month window.
- File the Medicaid application as soon as memory impairment is suspected.
- Keep hospital, emergency, imaging, lab and pharmacy bills with dates.
- Ask each provider for itemized statements for the months before filing.
